IP Library Granted Patent US 8,617,863
Granted Patent B2
US 8,617,863 · App. 12/995,447 · Granted Dec 31, 2013

Composition, method, and kit for preparing plasmin

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,617,863
App. No.
12/995,447
Filed
Mar 18, 2011
Granted
Dec 31, 2013
Kind
B2
Art Unit
1652
USPC
435/174
Abstract

A streptokinase immobilized on a surface, in particular an immobilized plasmin-resistant streptokinase, and compositions, methods and kits of utilizing same for preparing plasmin are provided.

Claims (30)

1. A method for preparing plasmin, the method comprising:

(a) contacting a composition comprising a plasminogen with a streptokinase immobilized on a matrix thereby converting the plasminogen to a plasmin,

wherein the streptokinase is a streptokinase mutant characterized as capable of activating plasminogen to plasmin, yet resistant to plasmin degradation relative to its corresponding wild-type streptokinase; and

wherein the streptokinase comprises an amino acid sequence having an amino acid residue other than lysine at a position corresponding to position 85, 412, or both positions, as shown in SEQ ID NO:1; and

(b) purifying the plasmin by a method comprising contacting the composition with a plasmin-binding matrix so that the plasmin is retained by the plasmin-binding matrix, the plasmin-binding matrix having a molecule disposed thereon having affinity for the plasmin.

2. The method of claim 1 , wherein the streptokinase comprises the amino acid sequence shown as amino acid residues 27 through 440 of SEQ ID NO:2.

3. The method of claim 1 , wherein the streptokinase, optionally, further comprises polar or charged amino acid residues comprising lysine, arginine, histidine, aspartic acid, glutamic acid, serine, threonine, asparagine, glutamine, tryosine or cysteine at one or more positions corresponding to positions 406-410 in SEQ ID NO:1.

4. The method of claim 1 , wherein the amino acid residue is glutamine or asparagine.

5. The method of claim 2 , wherein the streptokinase, optionally, further comprises polar or charged amino acid residues comprising lysine, arginine, histidine, aspartic acid, glutamic acid, serine, threonine, asparagine, glutamine, tryosine or cysteine at one or more positions corresponding to positions 406-410 in SEQ ID NO:1.

6. The method of claim 1 , wherein the streptokinase is recombinant.

7. The method of claim 1 , wherein the streptokinase comprises an affinity tag.

8. The method of claim 7 , wherein the affinity tag comprises polyhistidine, thioredoxin, or glutathione-S-transferase (GST).

9. The method of claim 7 , wherein the affinity tag comprises polyhistidine.

10. The method of claim 1 , wherein the streptokinase is immobilized on a matrix comprising immobilized metal ion adsorption chromatography.

11. The method of claim 1 , wherein the plasma-binding matrix is benzamidine-coupled to crosslinked beaded agarose.

12. The method of claim 1 , wherein the plasminogen is plasma-derived.

13. The method of claim 1 , wherein the plasminogen is recombinant.

14. A method for preparing plasmin, the method comprising:

(a) contacting a composition comprising a plasminogen with a streptokinase immobilized on a matrix thereby converting the plasminogen to a plasmin,

wherein the streptokinase is a streptokinase mutant characterized as capable of activating plasminogen to plasmin, yet resistant to plasmin degradation relative to its corresponding wild-type streptokinase;

wherein the streptokinase comprises an amino acid sequence having an amino acid residue other than lysine at a position corresponding to position 85, 412, or both positions, as shown in SEQ ID NO:1; and

wherein the streptokinase comprises a polyhistidine affinity tag; and

(b) purifying the plasmin by a method comprising contacting the composition with a plasmin-binding matrix so that the plasmin is retained by the plasmin-binding matrix;

wherein the plasma-binding matrix is benzamidine-coupled to crosslinked beaded agarose.

15. The method of claim 14 , wherein the streptokinase comprises the amino acid sequence shown as amino acid residues 27 through 440 of SEQ ID NO:2.

16. The method of claim 14 , wherein the streptokinase, optionally, further comprises polar or charged amino acid residues comprising lysine, arginine, histidine, aspartic acid, glutamic acid, serine, threonine, asparagine, glutamine, tryosine or cysteine at one or more positions corresponding to positions 406-410 in SEQ ID NO:1.

17. The method of claim 14 , wherein the amino acid residue is glutamine or asparagine.

18. The method of claim 15 , wherein the streptokinase, optionally, further comprises polar or charged amino acid residues comprising lysine, arginine, histidine, aspartic acid, glutamic acid, serine, threonine, asparagine, glutamine, tryosine or cysteine at one or more positions corresponding to positions 406-410 in SEQ ID NO:1.

19. The method of claim 14 , wherein the plasminogen is plasma-derived.

20. The method of claim 14 , wherein the plasminogen is recombinant.

Assignments (28)
RELEASE OF SECURITY INTEREST Recorded Apr 15, 2026
From: EUROPEAN INVESTMENT BANK
To: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC (F/K/A GRIFOLS THERAPEUTICS, INC.); GRIFOLS BIOLOGICALS LLC (F/K/A GRIFOLS BIOLOGICALS, INC.); BIOMAT USA, INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC; TALECRIS PLASMA RESOURCES, INC.
Reel/Frame 075416/0633 →
RELEASE OF SECURITY INTEREST Recorded Apr 15, 2026
From: EUROPEAN INVESTMENT BANK
To: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC (F/K/A GRIFOLS THERAPEUTICS, INC.); GRIFOLS BIOLOGICALS LLC (F/K/A GRIFOLS BIOLOGICALS, INC.); BIOMAT USA, INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC; TALECRIS PLASMA RESOURCES, INC.
Reel/Frame 075416/0718 →
RELEASE OF SECURITY INTEREST Recorded Apr 15, 2026
From: EUROPEAN INVESTMENT BANK
To: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC (F/K/A GRIFOLS THERAPEUTICS, INC.); GRIFOLS BIOLOGICALS LLC (F/K/A GRIFOLS BIOLOGICALS, INC.); BIOMAT USA, INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC; TALECRIS PLASMA RESOURCES, INC.
Reel/Frame 075416/0698 →
SECURITY INTEREST Recorded May 14, 2024
From: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC; GRIFOLS BIOLOGICALS LLC; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC
To: THE BANK OF NEW YORK MELLON, LONDON BRANCH
Reel/Frame 067409/0127 →
PARTIAL RELEASE OF SECURITY INTEREST Recorded Dec 10, 2021
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: BIOMAT USA, INC.; TALECRIS PLASMA RESOURCES, INC.
Reel/Frame 058480/0221 →
PARTIAL RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME NO. 51024/0453 Recorded Dec 7, 2021
From: EUROPEAN INVESTMENT BANK
To: BIOMAT USA, INC.; TALECRIS PLASMA RESOURCES, INC.
Reel/Frame 058351/0064 →
PARTIAL RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME NO. 51024/0317 Recorded Dec 7, 2021
From: EUROPEAN INVESTMENT BANK
To: BIOMAT USA, INC.; TALECRIS PLASMA RESOURCES, INC.
Reel/Frame 058518/0524 →
PARTIAL RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME NO. 51021/0593 Recorded Dec 7, 2021
From: EUROPEAN INVESTMENT BANK
To: BIOMAT USA, INC.; TALECRIS PLASMA RESOURCES, INC.
Reel/Frame 058350/0980 →
PARTIAL RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME NO. 51047/0139 Recorded Dec 1, 2021
From: THE BANK OF NEW YORK MELLON, LONDON BRANCH
To: BIOMAT USA, INC.; TALECRIS PLASMA RESOURCES, INC.
Reel/Frame 058292/0564 →
SECURITY INTEREST Recorded Nov 18, 2019
From: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC; GRIFOLS BIOLOGICALS LLC; BIOMAT USA, INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC; TALECRIS PLASMA RESOURCES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 051047/0123 →
SECURITY INTEREST Recorded Nov 18, 2019
From: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC; GRIFOLS BIOLOGICALS LLC; BIOMAT USA, INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC; TALECRIS PLASMA RESOURCES, INC.
To: THE BANK OF NEW YORK MELLON, LONDON BRANCH, AS NOTES COLLATERAL AGENT
Reel/Frame 051047/0139 →
RELEASE OF SECURITY INTEREST Recorded Nov 18, 2019
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC (FORMERLY KNOWN AS GRIFOLS THERAPEUTICS, INC.); GRIFOLS BIOLOGICALS LLC (FORMERLY KNOWN AS GRIFOLS BIOLOGICALS, INC.); BIOMAT USA, INC.; GRIFOLS DIAGNOSTIC SOLUTIONS INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC
Reel/Frame 051047/0153 →
SECURITY INTEREST Recorded Nov 15, 2019
From: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC; GRIFOLS BIOLOGICALS LLC; BIOMAT USA, INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC; TALECRIS PLASMA RESOURCES, INC.
To: EUROPEAN INVESTMENT BANK
Reel/Frame 051024/0453 →
SECURITY INTEREST Recorded Nov 15, 2019
From: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC; GRIFOLS BIOLOGICALS LLC; BIOMAT USA, INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC; TALECRIS PLASMA RESOURCES, INC.
To: EUROPEAN INVESTMENT BANK
Reel/Frame 051024/0317 →
RELEASE OF SECURITY INTEREST Recorded Nov 15, 2019
From: EUROPEAN INVESTMENT BANK
To: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC (FORMERLY KNOWN AS GRIFOLS THERAPEUTICS, INC.); GRIFOLS BIOLOGICALS LLC (FORMERLY KNOWN AS GRIFOLS BIOLOGICALS, INC.); BIOMAT USA, INC.; GRIFOLS DIAGNOSTIC SOLUTIONS INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.
Reel/Frame 051024/0722 →
RELEASE OF SECURITY INTEREST Recorded Nov 15, 2019
From: EUROPEAN INVESTMENT BANK
To: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC (FORMERLY KNOWN AS GRIFOLS THERAPEUTICS, INC.; GRIFOLS BIOLOGICALS LLC (FORMERLY KNOWN AS GRIFOLS BIOLOGICALS, INC.); BIOMAT USA, INC.; GRIFOLS DIAGNOSTIC SOLUTIONS INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC
Reel/Frame 051064/0021 →
SECURITY INTEREST Recorded Nov 15, 2019
From: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC; GRIFOLS BIOLOGICALS LLC; BIOMAT USA, INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC; TALECRIS PLASMA RESOURCES, INC.
To: EUROPEAN INVESTMENT BANK
Reel/Frame 051021/0593 →
SECURITY INTEREST Recorded Sep 7, 2018
From: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS LLC; GRIFOLS BIOLOGICALS LLC; BIOMAT USA, INC.; GRIFOLS DIAGNOSTIC SOLUTIONS INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC
To: EUROPEAN INVESTMENT BANK, AS LENDER
Reel/Frame 047438/0836 →
CHANGE OF ADDRESS Recorded Jun 1, 2018
From: GRIFOLS THERAPEUTICS LLC
To: GRIFOLS THERAPEUTICS LLC
Reel/Frame 046286/0824 →
CHANGE OF NAME Recorded Jan 5, 2018
From: GRIFOLS THERAPEUTICS INC.
To: GRIFOLS THERAPEUTICS LLC
Reel/Frame 045008/0573 →
SECURITY INTEREST Recorded Dec 5, 2017
From: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS INC.; GRIFOLS BIOLOGICALS INC.; BIOMAT USA, INC.; GRIFOLS DIAGNOSTIC SOLUTIONS.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.
To: EUROPEAN INVESTMENT BANK, AS LENDER
Reel/Frame 044696/0846 →
SECURITY INTEREST Recorded Dec 5, 2017
From: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.; GRIFOLS THERAPEUTICS INC.; GRIFOLS BIOLOGICALS INC.; BIOMAT USA, INC.; GRIFOLS DIAGNOSTIC SOLUTIONS.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC
To: EUROPEAN INVESTMENT BANK, AS LENDER
Reel/Frame 044697/0725 →
SECURITY INTEREST Recorded Feb 7, 2017
From: GRIFOLS SHARED SERVICES NORTH AMERICA INC.; GRIFOLS THERAPEUTICS INC.; GRIFOLS BIOLOGICALS INC.; BIOMAT USA, INC.; GRIFOLS DIAGNOSTIC SOLUTIONS INC.; GRIFOLS WORLDWIDE OPERATIONS USA, INC.; GRIFOLS USA, LLC
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 041651/0487 →
RELEASE OF SECURITY INTEREST Recorded Feb 6, 2017
From: DEUTSCHE BANK AG NEW YORK BRANK
To: GRIFOLS THERAPEUTICS INC.; GRIFOLS SHARED SERVICES NORTH AMERICA INC.; GRIFOLS DIAGNOSTIC SOLUTIONS INC.
Reel/Frame 041638/0527 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 26390/0193 Recorded Jan 25, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: GRIFOLS, S.A.; GRIFOLS INC.; TALECRIS BIOTHERAPEUTICS, INC.
Reel/Frame 041494/0017 →
SECURITY AGREEMENT Recorded Feb 27, 2014
From: GRIFOLS INC.; GRIFOLS THERAPEUTICS INC.; GRIFOLS-CHIRON DIAGNOSTICS CORP.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032367/0001 →
CHANGE OF NAME Recorded Jun 18, 2013
From: TALECRIS BIOTHERAPEUTICS, INC.
To: GRIFOLS THERAPEUTICS INC.
Reel/Frame 030650/0819 →
SECURITY AGREEMENT Recorded Jun 3, 2011
From: GRIFOLS, S.A.; GRIFOLS INC.; TALECRIS BIOTHERAPEUTICS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 026390/0193 →